Overview

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Status:
Terminated

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb